HOME >> MEDICINE >> NEWS
MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy

New Orleans, La. (March 27, 2007) Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication. This restriction is due to theoretical safety concerns associated with small EKG changes noted in patients taking ranolazine.

Accordingly, the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes (MERLIN TIMI-36) study, presented today at the American College of Cardiologys 56th Annual Scientific Session, had the dual objectives to provide new long-term safety data on ranolazine in a high-risk population of patients with acute coronary syndromes (ACS) and to study the drugs efficacy in a broad population of people with unstable angina due to ACS. ACC.07 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists from around the world to further breakthroughs in cardiovascular medicine.

The efficacy data showed that ranolazine did not produce a statistically significant reduction in the composite endpoint of cardiovascular death, heart attack and recurrent ischemia (the primary efficacy endpoint of the study), but did show a statistically significant reduction in recurrent ischemia alone. The data showed no adverse trend in death or arrhythmia in patients receiving ranolazine.

Ranolazine is a novel anti-ischemic agent that, unlike other classes of anti-anginal therapy, does not significantly reduce heart rate or blood pressure. The MERLIN TIMI-36 study evaluated the safety and efficacy of ranolazine in the short- and long-term treatment of patients with non-ST elevation ACS.

The placebo-controlled, double-blind
'"/>

Contact: Leslie Humbel
lhumbel@spectrumscience.com
504-613-2418
American College of Cardiology
27-Mar-2007


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2019)... SAN JOSE, Calif. (PRWEB) , ... March 20, ... ... safety net health plan for Santa Clara County, announced that the National Committee ... Cal MediConnect (Medicare-Medicaid Plan) line of business. NCQA is a private, not-for-profit organization ...
(Date:3/20/2019)... ... 20, 2019 , ... TSI Healthcare, a national ... Electronic Health Record (EHR) solutions, received multiple top awards in the 2019 ... consecutive year TSI Healthcare has been honored by this selective international organization. In ...
(Date:3/20/2019)... ... 20, 2019 , ... EBSCO Health , the leading ... announced the certification of two decision aids by the Washington State Health Care ... Test: Yes or No? Currently, Washington is the only state requiring certification for ...
(Date:3/20/2019)... ... 2019 , ... The American Board of Family Medicine (ABFM) ... for ABFM Diplomates. The new website, available at http://www.theabfm.org , is designed ... a responsive design, providing functional access from a desktop, a tablet, or smartphone, ...
(Date:3/20/2019)... ... March 20, 2019 , ... Natreon has been ... of trivalent chromium chloride combined with extracts of amla and shilajit, that has ... patent, along with 7 clinical studies on Crominex®3+, establish this ingredient as the ...
Breaking Medicine News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... AltaPointe Health is taking part ... & Independent for Life (SAIL). At the core of the SAIL program is ... adults stay active and reduce their chances of falling. , Twenty-three AltaPointe ...
(Date:3/18/2019)... AVIV, Israel (PRWEB) , ... March 18, 2019 ... ... in nutrition-based intensive care unit (ICU) technology, today announced the publication of an ... into cutting-edge technologies that may advance this critical component of patient care into ...
(Date:3/17/2019)... LA JOLLA, Calif. (PRWEB) , ... March 17, ... ... revolutionizing the home sleep apnea test space announced a commercial agreement ... testing and treatment program. , Lofta will integrate Itamar’s clinically ...
Breaking Medicine Technology:
Cached News: